IDH2 Antibody

What is IDH2 and why is it an important research target?

IDH2 (Isocitrate Dehydrogenase 2) is a mitochondrial enzyme that catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid cycle, playing a crucial role in cellular metabolism. IDH2 has gained significant research interest due to its mutations being implicated in various cancers, particularly acute myeloid leukemia (AML) and gliomas. IDH2 impacts cellular respiration and energy balance through its enzymatic function . The enzyme is particularly important because mutant forms can acquire a neomorphic function, converting α-KG to 2-hydroxyglutarate (2-HG), an oncometabolite that can induce epigenetic alterations through inhibition of α-KG-dependent enzymes like TET2, leading to DNA hypermethylation and differentiation blocks in affected cells . Studying IDH2 provides insights into metabolic reprogramming in cancer cells and potential therapeutic targets.

How do I select the appropriate IDH2 antibody for my research application?

Selecting the appropriate IDH2 antibody requires careful consideration of several factors. First, determine the specific application (Western blot, immunohistochemistry, immunofluorescence, or immunoprecipitation) and choose an antibody validated for that technique. For instance, some antibodies like clone 1069032 (MAB11462) have been validated for both ICC in cell lines and IHC in human tissues , while others like 15932-1-AP show reactivity across multiple applications and species (human, mouse, rat) .

Second, consider the species reactivity needed - available antibodies have been validated in human, mouse, and rat samples, with some showing cross-reactivity with pig and chicken samples . Third, evaluate whether you need to detect wild-type IDH2 or specific mutant forms, as this will influence your choice. Finally, review the recommended dilutions for your application (e.g., 1:500-1:3000 for WB, 1:200-1:800 for IHC) and optimize these for your specific experimental conditions.

What are the structural and functional differences between IDH1, IDH2, and IDH3?

IDH1, IDH2, and IDH3 are three distinct isozymes of isocitrate dehydrogenase with important differences:

Cellular localization: IDH1 is cytosolic and peroxisomal, IDH2 is mitochondrial, and IDH3 is exclusively mitochondrial.

Cofactor preference: IDH1 and IDH2 use NADP+ as a cofactor (producing NADPH), while IDH3 uses NAD+ (producing NADH).

Structure: IDH1 and IDH2 function as homodimers, while IDH3 is a heterotetramer composed of α, β, and γ subunits.

Function in metabolism: IDH3 functions primarily in the TCA cycle, while IDH1 and IDH2 can catalyze the reverse reaction and are involved in metabolic regulation beyond energy production.

Cancer relevance: IDH1 and IDH2 mutations are common in various cancers and produce the oncometabolite 2-HG, while IDH3 mutations are rarely found in cancers.

These structural and functional differences explain why knockdown of IDH2 sometimes leads to compensatory increases in the expression of IDH1 and IDH3 subunits (α, β, and γ), as observed in some TNBC cell lines . This compensatory mechanism highlights the metabolic plasticity of cancer cells and the need to consider all isozymes when targeting IDH2.

What are the optimal protocols for detecting IDH2 in different cellular compartments?

Detecting IDH2 in different cellular compartments requires specific methodological approaches due to its primarily mitochondrial localization. For immunofluorescence staining, the following protocol has been validated:

• Fix cells with 4% paraformaldehyde (15 minutes) or 80% methanol (5 minutes)

• Permeabilize with 0.1% PBS-Tween for 20 minutes to allow antibody access to mitochondria

• Block with 5% normal serum in PBS containing 0.3% Triton X-100 for 1 hour

• Incubate with primary anti-IDH2 antibody (recommended range 1:50-1:200) overnight at 4°C

• Wash 3 times with PBS, then incubate with fluorophore-conjugated secondary antibody

• Counterstain with DAPI to visualize nuclei

• For mitochondrial colocalization, co-stain with mitochondrial markers such as MitoTracker or anti-TOMM20 antibody

For subcellular fractionation and Western blot analysis:

• Isolate mitochondrial, cytosolic, and nuclear fractions using standard differential centrifugation protocols

• Run equivalent protein amounts from each fraction on SDS-PAGE

• Transfer to membrane and probe with anti-IDH2 antibody (1:500-1:3000 dilution)

• Include compartment-specific marker controls (e.g., VDAC for mitochondria, β-tubulin for cytosol)

When analyzing patient samples, immunohistochemistry protocols need appropriate antigen retrieval. For optimal results, use TE buffer pH 9.0 or citrate buffer pH 6.0 with heat-induced epitope retrieval prior to antibody incubation at 1:200-1:800 dilution .

How can I optimize Western blot protocols for IDH2 detection in different tissue types?

Optimizing Western blot protocols for IDH2 detection across different tissue types requires attention to several key factors:

Tissue-specific lysis buffer selection:

• For brain, heart, and muscle tissues: Use RIPA buffer supplemented with 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, protease inhibitors, and phosphatase inhibitors

• For liver and kidney tissues: Add 1 mM DTT to standard lysis buffer to protect against oxidation

Protein loading considerations:

• IDH2 expression levels vary by tissue; adjust loading accordingly (typical range: 20-50 μg)

• For liver and heart tissues (high expression): Load 20-30 μg

• For other tissues: Load 40-50 μg

Antibody optimization:

• Initial dilution trials should include 1:500, 1:1000, 1:2000, and 1:3000

• Primary antibody incubation: Overnight at 4°C with gentle rocking

• Secondary antibody: Anti-rabbit HRP-conjugated (1:5000-1:10000) or fluorescent conjugates (1:20000)

Detection parameters:

• Expected molecular weight: 41-47 kDa (observed) vs 51 kDa (calculated)

• Positive controls should include Jurkat, HeLa, HEK-293, or HepG2 cell lysates

• Negative controls: IDH2 knockout samples or pre-incubation of antibody with blocking peptide

Optimization strategies for problematic tissues:

• For muscle tissues: Add 2% SDS to lysis buffer to improve solubilization

• For tissues with high lipid content: Pre-clear lysates by centrifugation at 20,000g for 20 minutes

• For tissues with high protease activity: Double the concentration of protease inhibitors

This protocol has been successfully used to detect IDH2 in multiple human cell lines and mouse/rat tissues including heart, skeletal muscle, liver, brain, and kidney .

What are the validated protocols for immunohistochemical detection of IDH2 in clinical specimens?

For immunohistochemical detection of IDH2 in clinical specimens, the following validated protocol has shown consistent results:

Tissue preparation and antigen retrieval:

• Fix tissues in 10% neutral buffered formalin for 24-48 hours

• Process and embed in paraffin according to standard protocols

• Cut sections at 4-5 μm thickness

• Perform heat-induced epitope retrieval using TE buffer pH 9.0 (preferred) or citrate buffer pH 6.0 at 95-98°C for 20 minutes

• Allow slides to cool to room temperature (approximately 20 minutes)

Staining procedure:

• Block endogenous peroxidase with 3% hydrogen peroxide for 10 minutes

• Block non-specific binding with 5% normal goat serum for 1 hour

• Incubate with primary anti-IDH2 antibody at 1:200-1:800 dilution (optimize for each tissue type)

• Incubate overnight at 4°C or for 1 hour at room temperature

• Wash 3 times with PBS-T (5 minutes each)

• Apply appropriate HRP-polymer secondary detection system (e.g., Anti-Mouse IgG VisUCyteTM HRP Polymer Antibody)

• Develop with DAB chromogen and counterstain with hematoxylin

• Dehydrate, clear, and mount with permanent mounting medium

Validation controls:

• Positive tissue controls: Human kidney (tubules show specific staining), colon cancer tissue

• Negative controls: Omit primary antibody or use IDH2-knockout tissue

• For mutant-specific detection: Include known positive and negative mutation status samples

This protocol has been successfully used to detect IDH2 in human kidney tissue, showing specific localization to the cytoplasm and kidney tubules and in human colon cancer tissue , providing reliable results for both research and clinical diagnostic applications.

How do I distinguish between wild-type and mutant IDH2 proteins in experimental settings?

Distinguishing between wild-type and mutant IDH2 proteins requires a multi-faceted approach combining molecular, biochemical, and immunological techniques:

Mutation-specific antibodies:

• Some commercial antibodies are specific for common mutations (R172K, R140Q)

• Validation using known positive and negative controls is essential

• Western blotting typically shows similar molecular weights between wild-type and mutant forms (41-47 kDa)

Functional assays:

• Enzymatic activity assays: Mutant IDH2 exhibits reduced normal catalytic activity (conversion of isocitrate to α-KG) and gained neomorphic activity (conversion of α-KG to 2-HG)

• 2-HG measurement: Quantify 2-HG levels by LC-MS/MS, as mutant IDH2 produces significantly elevated 2-HG levels compared to wild-type

• NADPH consumption rate: Monitor NADPH oxidation spectrophotometrically at 340 nm, as mutant enzymes show altered NADPH consumption patterns

Molecular techniques:

• Sequencing: Sanger sequencing or next-generation sequencing to identify specific mutations

• Allele-specific PCR: Design primers specific to common mutations (R172K, R172M, R140Q)

• Restriction fragment length polymorphism (RFLP): Some mutations create or destroy restriction enzyme sites

Downstream effects:

• Assess DNA hypermethylation patterns, a hallmark of mutant IDH2 activity

• Evaluate expression of genes affected by IDH2 mutations

• Monitor STAT3 activation levels, which differ between various IDH2 mutants

The choice of method depends on the research question, available resources, and type of samples being analyzed. For clinical specimens, immunohistochemistry with mutation-specific antibodies combined with 2-HG measurements provides a practical approach for distinguishing wild-type from mutant IDH2.

What are the established protocols for studying the effects of IDH2 mutations on cellular metabolism?

Studying the effects of IDH2 mutations on cellular metabolism requires a comprehensive approach that combines metabolomic, genomic, and functional analyses:

Metabolite profiling protocol:

• Extract metabolites using methanol/chloroform/water (1:1:1) mixture

• Analyze using liquid chromatography-mass spectrometry (LC-MS)

• Key metabolites to quantify:

  • 2-hydroxyglutarate (2-HG) - dramatically increased in mutant cells

  • α-ketoglutarate (α-KG) - often depleted

  • Isocitrate - may accumulate

  • TCA cycle intermediates - often altered

Isotope tracing studies:

• Culture cells with 13C-labeled glucose or glutamine

• Extract metabolites at defined time points

• Perform LC-MS/MS to track carbon flow through metabolic pathways

• Compare labeling patterns between wild-type and mutant IDH2-expressing cells

Oxygen consumption and extracellular acidification measurements:

• Use Seahorse XF Analyzer to measure:

  • Oxygen consumption rate (OCR) - indicator of mitochondrial respiration

  • Extracellular acidification rate (ECAR) - indicator of glycolysis

• Compare baseline rates and responses to metabolic inhibitors between wild-type and mutant IDH2 cells

Redox state assessment:

• Measure NADP+/NADPH ratios using enzymatic cycling methods

• Determine GSH/GSSG ratios to assess cellular redox state

• Evaluate reactive oxygen species (ROS) levels using fluorescent probes

Gene expression analysis protocol:

• Perform RNA-seq to identify metabolic genes affected by IDH2 mutations

• Use qRT-PCR to validate expression changes in key metabolic enzymes

• Focus on genes involved in:

  • TCA cycle regulation

  • Glutamine metabolism

  • Lipid synthesis

  • Epigenetic modifiers

Epigenetic profiling:

• Use the HELP assay (HpaII tiny fragment enrichment by ligation-mediated PCR) to detect cytosine methylation levels

• Perform ChIP-seq for histone modifications affected by α-KG-dependent enzymes

• Validate with targeted bisulfite sequencing of CpG islands

These protocols have revealed that different IDH2 mutations (R172K, R172M, and R140Q) can produce varying levels of 2-HG and have distinct effects on cellular metabolism and growth rates , highlighting the importance of studying mutation-specific effects rather than generalizing across all IDH2 mutations.

How can IDH2 antibodies be used to identify potential therapeutic targets in IDH2-mutant cancers?

IDH2 antibodies serve as valuable tools for identifying potential therapeutic targets in IDH2-mutant cancers through multiple research approaches:

Target validation and expression analysis:

• Use immunohistochemistry with IDH2 antibodies to confirm expression and localization in primary patient samples

• Quantify expression levels across different cancer subtypes to identify correlations with clinical outcomes

• Compare expression between mutant and wild-type IDH2 tumors to identify differential pathway activation

Protein interaction studies:

• Employ co-immunoprecipitation with IDH2 antibodies to identify novel binding partners

• Use proximity ligation assays to visualize and quantify protein-protein interactions in situ

• Cross-reference identified interactors with druggable protein databases to find novel therapeutic targets

Post-translational modification analysis:

• Use specific antibodies to detect key regulatory modifications like K413-acetylation

• Investigate how these modifications regulate mutant IDH2 activity

• Target enzymes responsible for these modifications, such as those regulated by FLT3 WT or ITD mutant that restrict mutant IDH2 activity through K413-acetylation

Therapeutic response monitoring:

• Use IDH2 antibodies to track protein expression and localization changes following treatment

• Compare 2-HG levels with IDH2 expression/modification to assess inhibitor efficacy

• Develop predictive biomarkers for response to IDH2 inhibitors

Combination therapy identification:

• Screen for synergistic effects between IDH2 inhibitors and other targeted agents

• Use IDH2 antibodies to monitor pathway reactivation mechanisms

• Identify resistance mechanisms to IDH2 inhibition through phosphoproteomic analysis

IDH2 wildtype expression in other cancers:

• Evaluate IDH2 wildtype overexpression in cancers like triple-negative breast cancer (TNBC)

• Validate IDH2 as a potential therapeutic target using knockdown/overexpression experiments

• Investigate compensatory mechanisms involving other IDH isoforms when IDH2 is inhibited

These approaches have helped identify that tumorigenic properties, response to chemotherapeutic agents, and baseline activation of STAT3 differ between IDH2 mutant forms , suggesting that therapeutic strategies may need to be tailored to specific mutations rather than treating all IDH2 mutations equivalently.

How do changes in IDH2 activity influence epigenetic modifications and gene expression patterns?

IDH2 mutations significantly impact epigenetic landscapes through multiple interconnected mechanisms, primarily driven by the production of the oncometabolite 2-hydroxyglutarate (2-HG):

DNA methylation alterations:

• IDH2 mutations result in a hypermethylation phenotype in leukemia patients, identified through HELP assay analysis

• Using stringent criteria (absolute log2 difference in methylation > 1.5, p<0.05 with Benjamini-Hochberg correction), 45 differentially methylated regions (DMRs) have been identified in IDH1/2 mutant samples compared to wild-type

• These DMRs are universally hypermethylated in IDH1/2 mutant samples

• Validation of HELP assay results using MassArray Epityping shows high correlation (r= −0.87)

Mechanism of epigenetic dysregulation:

• Mutant IDH2 produces 2-HG, which competitively inhibits α-KG-dependent dioxygenases

• Key inhibited enzymes include:

  • TET family DNA hydroxylases (particularly TET2)

  • Jumonji-domain histone demethylases

• This inhibition leads to:

  • Decreased 5-hydroxymethylcytosine (5hmC) levels

  • Increased repressive histone marks (H3K9me3, H3K27me3)

  • Decreased active histone marks (H3K4me3)

Cellular differentiation impact:

• The epigenetic alterations caused by IDH2 mutations impair hematopoietic differentiation

• This differentiation block is a hallmark feature of AML and contributes to leukemogenesis

• Similar effects are observed in gliomas, contributing to the characteristic proneural phenotype

Gene expression changes:

• Hypermethylation leads to silencing of differentiation-associated genes

• Altered histone modifications reinforce transcriptional repression

• These changes collectively promote a stem-like phenotype in affected cells

Therapeutic implications:

• IDH2 inhibitors (e.g., enasidenib) reduce 2-HG production

• This reduction allows reactivation of TET enzymes and histone demethylases

• Gradual epigenetic reprogramming occurs, potentially restoring normal differentiation patterns

The study of these epigenetic mechanisms requires integration of DNA methylation analysis (HELP assay, bisulfite sequencing), histone modification profiling (ChIP-seq), gene expression analysis (RNA-seq), and functional differentiation assays to fully characterize the impact of IDH2 mutations on cellular programming.

What are the most effective strategies for validating IDH2 knockdown or knockout experiments?

Validating IDH2 knockdown or knockout experiments requires a multi-layered approach to confirm target specificity and rule out compensatory mechanisms or off-target effects:

Molecular validation protocols:

mRNA level validation:

• Quantitative RT-PCR using primers targeting different exons of IDH2

• RNA-seq to assess global impact and potential off-target effects

• Northern blotting for alternative transcript analysis

Protein level validation:

• Western blotting with at least two different validated IDH2 antibodies

• Recommended antibody dilutions: 1:500-1:3000

• Immunofluorescence to confirm subcellular localization changes

• Flow cytometry for high-throughput quantification

Functional validation strategies:

Enzymatic activity assays:

• Measure conversion of isocitrate to α-ketoglutarate

• Quantify NADPH production spectrophotometrically

• Assess 2-HG levels in mutant IDH2 knockdown models

Metabolic impact assessment:

• Metabolomics profiling of TCA cycle intermediates

• Oxygen consumption rate measurements

• Extracellular acidification rate analysis

Rescue experiments to confirm specificity:

A critical validation approach involves rescue experiments using IDH2 re-expression:

• Construct shRNA-resistant IDH2 expression vectors (with silent mutations in the shRNA target sequence)

• Re-express IDH2 in knockdown cells to restore function

• Measure restoration of proliferation and other phenotypes

In published examples, rescue experiments successfully restored cell proliferation in HCC38 and MDA-MB-231 cells with IDH2 knockdown, confirming that growth suppression was specifically due to IDH2 depletion rather than off-target effects .

Compensatory mechanism assessment:

A crucial consideration is evaluating potential compensatory increases in related enzymes:

• Monitor IDH1 and IDH3 (α, β, and γ subunits) expression by qRT-PCR and Western blot

• Published data show compensatory increases in IDH1, IDH3α, β, and γ in some shRNA knockdown models (sh-IDH2 #2) but not others (sh-IDH2 #1)

• This variable compensation may explain differences in knockdown efficiency and phenotypic effects

CRISPR/Cas9 knockout validation:

• Sequence confirmation of the targeted genomic locus

• Analysis of potential off-target sites identified by in silico prediction tools

• Assessment of clonal heterogeneity in pooled knockout populations

These comprehensive validation approaches ensure that observed phenotypes are genuinely attributable to IDH2 modulation rather than experimental artifacts or compensatory mechanisms.

How can researchers accurately measure and interpret 2-hydroxyglutarate (2-HG) levels produced by different IDH2 mutants?

Accurately measuring and interpreting 2-hydroxyglutarate (2-HG) levels produced by different IDH2 mutants requires sophisticated analytical techniques and careful experimental design:

Analytical methods for 2-HG quantification:

Liquid Chromatography-Mass Spectrometry (LC-MS/MS):

• Gold standard method for accurate quantification

• Protocol highlights:

  • Extract metabolites from cells/tissues using methanol:water (80:20)

  • Separate using HILIC column chromatography

  • Detect using multiple reaction monitoring (MRM)

  • Quantify against isotopically labeled internal standards

  • Limit of detection: 30-50 nM

Enzymatic assays:

• More accessible but less specific than LC-MS/MS

• Based on conversion of 2-HG to α-KG by D-2-hydroxyglutarate dehydrogenase

• Couple with NAD+/NADH conversion for spectrophotometric detection

Gas Chromatography-Mass Spectrometry (GC-MS):

• Requires derivatization of 2-HG

• Good for simultaneous profiling of multiple TCA cycle metabolites

Experimental design considerations:

Cell type selection:

• Matched isogenic cell lines expressing different IDH2 mutants

• Control for genetic background effects on metabolism

Mutation-specific analysis:

• Compare the three most frequent mutations: R172K, R172M, and R140Q

• Research shows these produce different 2-HG levels

Compartmentalization assessment:

• Measure 2-HG in different cellular compartments

• Separate mitochondrial and cytosolic fractions before analysis

Time-course measurements:

• Monitor 2-HG accumulation over time

• Assess steady-state levels vs. production rates

Interpretation frameworks:

Correlation with biological effects:

• Different IDH2 mutations produce varying 2-HG levels

• Paradoxically, higher 2-HG levels may inversely correlate with growth rates

• Compare 2-HG production with:

  • Cell proliferation rates

  • Differentiation status

  • DNA/histone methylation patterns

Enantiomer consideration:

• IDH1/2 mutations primarily produce (R)-2-HG, not (L)-2-HG

• Methods should distinguish between enantiomers for accurate interpretation

• LC-MS/MS with chiral columns can separate (R)- and (L)-2-HG

Contextual effects:

• (R)-2-HG can have opposing effects depending on cellular context:

  • Stimulates growth in non-transformed cells

  • Displays antitumor activity in cells with wild-type IDH2

  • Effect can switch from mitogenic to antiproliferative when cells are transformed with oncogenic RAS

Normal range establishment:

• Define baseline 2-HG levels in different tissues

• Establish thresholds for pathological significance

• Account for potential dietary and environmental influences

These methodological approaches allow researchers to accurately quantify and meaningfully interpret the varying levels of 2-HG produced by different IDH2 mutants, enabling more precise understanding of mutation-specific effects in cancer and other diseases.

What are common pitfalls in IDH2 antibody-based experiments and how can they be overcome?

Researchers frequently encounter several challenges when working with IDH2 antibodies. Here are common pitfalls and their solutions:

Non-specific binding and high background:

• Problem: Multiple bands in Western blot or diffuse staining in IHC/IF

• Solutions:

  • Optimize blocking conditions (try 5% BSA instead of milk for phospho-specific detection)

  • Increase washing duration and frequency (5 washes of 5 minutes each)

  • Titrate primary antibody concentration (test range from 1:200-1:2000)

  • For IHC, use appropriate antigen retrieval (TE buffer pH 9.0 recommended for IDH2)

  • Add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions

  • Pre-absorb antibody with cell/tissue lysate from IDH2 knockout samples

Inconsistent detection across sample types:

• Problem: Variation in signal intensity between tissues or cell lines

• Solutions:

  • Optimize protein extraction methods for each tissue type

  • For hard-to-lyse tissues, use mechanical disruption plus enzymatic digestion

  • Adjust protein loading: higher amounts (40-50 μg) for low-expressing samples

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use enhanced sensitivity detection systems for low abundance samples

Distinguishing between IDH isoforms:

• Problem: Cross-reactivity with IDH1 or IDH3 due to sequence homology

• Solutions:

  • Verify antibody specificity using IDH2 knockout controls

  • Perform side-by-side comparison with known IDH1 and IDH3 antibodies

  • Use subcellular fractionation to separate mitochondrial (IDH2/IDH3) from cytosolic (IDH1) fractions

  • For critical experiments, confirm findings using multiple antibody clones

Mutation-specific detection challenges:

• Problem: Difficulty distinguishing wild-type from mutant IDH2

• Solutions:

  • Use mutation-specific antibodies when available

  • Complement antibody detection with functional assays (2-HG production)

  • Implement parallel genomic verification (Sanger sequencing/digital droplet PCR)

  • Consider using proximity ligation assays to detect mutation-specific interactions

Fixation and processing artifacts:

• Problem: Loss of IDH2 immunoreactivity in fixed tissues

• Solutions:

  • Limit fixation time in formalin (24-48 hours optimal)

  • Test multiple antigen retrieval protocols (citrate pH 6.0 vs. TE pH 9.0)

  • Use freshly cut sections (within 1 week of cutting)

  • Consider using alternative fixatives for sensitive epitopes

Standardization and quantification issues:

• Problem: Inconsistent quantification between experiments

• Solutions:

  • Include common reference samples across blots/staining batches

  • Use automated image analysis software with consistent parameters

  • For Western blots, verify linear range of detection for quantification

  • Include graduated positive controls to establish standard curves

These troubleshooting approaches will significantly improve reliability and reproducibility of IDH2 antibody-based experiments across different research applications.

What methods are most effective for studying IDH2 protein-protein interactions and post-translational modifications?

Studying IDH2 protein-protein interactions and post-translational modifications requires specialized techniques to preserve native interactions and labile modifications. Here are the most effective methods:

Protein-Protein Interaction Methods:

Co-Immunoprecipitation (Co-IP):

• Optimize lysis conditions to preserve interactions:

  • Use gentle, non-denaturing buffers (150mM NaCl, 50mM Tris pH 7.5, 1% NP-40)

  • Include phosphatase inhibitors (sodium orthovanadate, sodium fluoride)

  • Add protease inhibitor cocktail

• Protocol refinements:

  • Pre-clear lysates with Protein A/G beads to reduce background

  • Use 2-5 μg antibody per 500 μg protein lysate

  • Incubate overnight at 4°C with gentle rotation

  • Perform stringent washes (at least 4) with decreasing salt concentrations

  • Elute with gentle methods (non-reducing SDS loading buffer at room temperature)

Proximity Ligation Assay (PLA):

• Allows visualization of protein interactions in situ

• Particularly useful for transient or compartment-specific interactions

• Protocol highlights:

  • Fix cells with 4% paraformaldehyde (10 minutes)

  • Permeabilize with 0.2% Triton X-100 (10 minutes)

  • Block with 5% BSA (1 hour)

  • Incubate with primary antibodies from different species

  • Follow with PLA-specific secondary antibodies and amplification steps

Chromatin Immunoprecipitation (ChIP):

• For studying IDH2 interactions with chromatin components

• Critical parameters:

  • Crosslink with 1% formaldehyde (10 minutes)

  • Sonicate to achieve 200-500bp DNA fragments

  • Use IDH2 antibodies validated for ChIP applications

Post-Translational Modification Analysis:

Phosphorylation:

• Preserve phosphorylation states during lysis:

  • Include phosphatase inhibitors (10mM sodium fluoride, 1mM sodium orthovanadate)

  • Use PhosSTOP tablets (Roche) in lysis buffer

• Detection methods:

  • Phospho-specific antibodies when available

  • Phos-tag SDS-PAGE for mobility shift detection

  • LC-MS/MS with titanium dioxide enrichment

Acetylation:

• IDH2 K413-acetylation is particularly important as it restricts mutant IDH2 activity

• Preservation strategies:

  • Include deacetylase inhibitors (5mM sodium butyrate, 1μM trichostatin A)

  • Use NETN buffer with deacetylase inhibitors for lysis

• Detection approaches:

  • Anti-acetyl-lysine antibodies for immunoprecipitation

  • Site-specific acetyl-IDH2 antibodies if available

  • Mass spectrometry with acetyl-lysine enrichment

Mass Spectrometry-based approaches:

• Most comprehensive method for PTM discovery

• Sample preparation considerations:

  • In-gel or in-solution digestion with trypsin

  • Enrichment methods for specific modifications

  • Fractionation to reduce sample complexity

• Analytical strategies:

  • Data-dependent acquisition for discovery

  • Parallel reaction monitoring for targeted quantification

  • SILAC or TMT labeling for quantitative comparisons

CRISPR-based mutation studies:

• Generate lysine-to-arginine (K→R) or lysine-to-glutamine (K→Q) mutations to mimic non-acetylated or constitutively acetylated states

• Assess functional consequences of mutation on:

  • Enzymatic activity (normal and neomorphic)

  • 2-HG production

  • Protein-protein interactions

  • Cellular phenotypes

These methods have revealed that K413-acetylation of IDH2 can be regulated by FLT3 WT or ITD mutant, with 52-55% of total IDH2 protein estimated to be K413-acetylated in human primary AML cells . This acetylation restricts mutant IDH2 activity, potentially optimizing 2-HG levels for leukemogenesis.

How can researchers design comprehensive experiments to study the complex roles of IDH2 in different cancer types?

Designing comprehensive experiments to study IDH2's roles across cancer types requires a multi-dimensional approach that integrates molecular, cellular, and translational research strategies:

Comparative Expression Profiling Framework:

Cancer-type specific expression analysis:

• Analyze IDH2 expression across cancer types using tissue microarrays

• Develop a standardized IHC protocol using validated antibodies at 1:200-1:800 dilution

• Compare expression patterns with clinical outcomes in each cancer type

• Create a comprehensive table of expression patterns:

Mutation-Specific Functional Analysis Design:

Isogenic cell model development:

• Generate cell lines with common IDH2 mutations (R172K, R172M, R140Q) using CRISPR knock-in

• Create paired wild-type and mutant cell lines from multiple cancer types

• Assess differential effects on:

  • Proliferation rates (which inversely correlate with 2-HG levels)

  • Migration and invasion capabilities

  • Therapeutic response patterns

  • Metabolic dependencies

Metabolic Network Analysis Protocol:

Integrated metabolomic approach:

• Perform untargeted metabolomics to identify perturbed pathways in IDH2-mutant cells

• Follow with stable isotope tracing using 13C-glucose and 13C-glutamine

• Map metabolic flux differences between:

  • IDH2 wild-type vs. mutant cells

  • Different IDH2 mutations

  • Various cancer types

Context-Dependent Effects Evaluation:

Microenvironment influence assessment:

• Culture cells under varying conditions:

  • Normoxia vs. hypoxia

  • Glucose abundance vs. restriction

  • 2D vs. 3D culture systems

• Test how environmental factors modulate IDH2 activity and mutation effects

• Investigate the paradoxical effects of 2-HG:

  • Growth-stimulating in non-transformed cells

  • Growth-inhibitory in wild-type IDH2 tumors

  • Effect switching from mitogenic to antiproliferative with oncogenic RAS

Therapeutic Response Characterization:

Drug sensitivity profiling:

• Conduct systematic testing of IDH2 inhibitors against different mutations

• Assess combination therapies based on synthetic lethal interactions

• Develop response prediction models based on:

  • Specific IDH2 mutation (R172K vs. R172M vs. R140Q)

  • Genetic background (presence of co-mutations)

  • Metabolic state (2-HG levels, α-KG/2-HG ratio)

Translational Research Integration:

Patient-derived models:

• Establish patient-derived xenografts or organoids harboring various IDH2 alterations

• Validate findings from cell line studies in these models

• Correlate in vitro findings with clinical outcomes

Temporal Analysis of Disease Progression:

Clonal evolution tracking:

• Monitor IDH2 mutations as potential early events in carcinogenesis

• Assess how IDH2 mutations influence subsequent mutation acquisition

• Develop models of tumor evolution in IDH2-mutant cancers

This comprehensive experimental framework allows researchers to systematically investigate the complex and context-dependent roles of IDH2 across different cancer types, accounting for mutation-specific effects, metabolic influences, and therapeutic implications.

What are the key considerations for interpreting IDH2 antibody-based research results in both basic science and clinical contexts?

Interpreting IDH2 antibody-based research results requires critical evaluation of technical aspects and biological context in both basic science and clinical applications. Researchers should consider that different IDH2 mutations (R172K, R172M, R140Q) exhibit distinct biological behaviors despite their shared ability to produce 2-hydroxyglutarate (2-HG) . This heterogeneity extends to tumorigenic properties, chemosensitivity profiles, and activation of signaling pathways like STAT3 .

When evaluating antibody-based results, technical considerations include antibody specificity, optimal dilution ranges (1:500-1:3000 for WB, 1:200-1:800 for IHC) , and appropriate positive and negative controls. Researchers should validate findings using multiple antibodies and complementary techniques, particularly when distinguishing between wild-type and mutant IDH2 or when assessing post-translational modifications like K413-acetylation that can regulate enzyme activity .

In clinical contexts, interpretation must consider tissue-specific IDH2 expression patterns, the documented expression in various cell lines and tissues (including breast cancer, melanoma, kidney, and multiple other tissues) , and the different prognostic implications of IDH2 mutations across cancer types. While (R)-2-HG production in glioblastoma correlates with favorable patient survival, it associates with worse prognosis in AML patients , highlighting the context-dependent nature of IDH2 biology.

This complexity underscores the importance of integrated approaches combining antibody-based detection with functional assays, genetic analysis, and metabolite quantification to fully interpret the significance of IDH2 findings in both research and clinical settings.